Global cancer immunotherapy sales share by type 2021 forecast

This statistic depicts the market share forecast for top immuno-oncology companies worldwide in 2021. By 2021, it is predicted that Bristol-Myers Squibb will account for 34 percent of immuno-oncology sales worldwide.

Market share forecast for top immuno-oncology companies worldwide in 2021*

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% discount until December 20th
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

March 2016

Region

Worldwide

Survey time period

as of March 2016

Supplementary notes

* Based on sales. Immuno-oncology sales comprises immune checkpoint inhibitors, therapeutic vaccines, oncolytic viral therapy, and T cell therapy (tumor-targeted mAbs excluded).
** Merck KGaA-Pfizer alliance to co-develop and co-commercialize PD-L1 inhibitor, avelumab.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Oncology"

Further Content: You might find this interesting as well

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.